BSE: 540468
KMS Medisurgi Limited
Operates in the Healthcare Equipment & Supplies space, classified under medical equipment and supplies. FY26 revenue from operations was Rs. 1,220.85 lakhs, down from Rs. 1,393.86 lakhs the prior year (an approximate 12% decline), while profit after tax fell to Rs. 24.55 lakhs from Rs. 43.98 lakhs. Materials are the dominant cost line at 72.3% of revenue, followed by employee costs at 10.7% and other operating expenses at 9.7%, consistent with a stock-and-distribution model for physical medical products. Property, plant and equipment rose from Rs. 167.98 lakhs to Rs. 298.28 lakhs between H1 FY25 and H1 FY26, indicating capital investment during the period. The FY2024-25 annual report flags a planned expansion into adhesive tapes for automotive and electrical applications, extending beyond medical supplies. Cash flow from operations was Rs. 151.34 lakhs in FY26. The company is registered in Mumbai and listed on the BSE SME Platform, and operates under SME exchange exemptions from several corporate governance disclosures. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Medical equipment & supplies, Adhesive tapes for automotive and electrical applications. Small-cap medical equipment and supplies distributor/trader with planned diversification into industrial adhesive tapes
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 10 | 11 | 14 | 14 | 12 |
| EBITDA (ex other income) | — | — | — | — | — |
| margin % | — | — | — | — | — |
| Owners' profit | — | — | — | — | — |
| EPS, as reported (₹) | 0.65 | 1.74 | 1.38 | 1.33 | 0.74 |
| ROE % · ROCE % | — · 4.2 | — · 8.0 | — · 7.6 | — · 7.7 | — · 4.8 |
| Debt / equity (x) | — | — | — | — | — |
| Cash from operations | (0) | 0 | 1 | 1 | 2 |
| Capex | — | — | — | 0 | (2) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 5 | 7 | 7 | 8 | 6 | 7 | 6 |
| Profit before tax | 0 | 0 | 1 | (0) | 0 | 1 | 0 | 0 |
| Net profit | — | — | — | — | — | — | — | — |
| EPS (₹) | 0.78 | 0.95 | 1.83 | (0.45) | 0.24 | 1.09 | 0.70 | 0.04 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 14,679 | 46.6 | 4.66 | 26.9 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L | 1,644 | 10.5 | 4.27 | 30.8 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,572 | 141.4 | 2.48 | 13.7 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 984 | 31.6 | 4.03 | 21.1 | 11.8 | 11.0 | — | 22.3 |
| Hemant Surgical Industries Lim | 761 | 29.1 | — | — | — | 16.7 | — | — |
| FABTECH TECHNOLOGIES LTD | 554 | 9.0 | 1.32 | 8.9 | 9.1 | 10.7 | — | 9.9 |
| Prevest Denpro Limited | 457 | 15.4 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 281 | 57.5 | 1.55 | 33.8 | 1.2 | 2.7 | (7.2) | 13.0 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 64.2 | 21.2 | 14 of 16 | 13% |
| ROCE | 3.6 | 11.3 | 14 of 17 | 19% |
| Revenue growth | (16.9) | 13.9 | 13 of 13 | 0% |
| Market cap | 44 | 165 | 13 of 17 | 25% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 21 Oct 2026 · Corporate governance report not applicable as company is on BSE SME Platform | compliance | minimal | — | — |
| 13 Oct 2026 · Compliance certificate under SEBI Regulation 74(5) for Q2 FY27 | compliance | minimal | — | — |
| 1 Oct 2026 · Independent Director completes second term and ceases | management changes | medium | — | — |
| 1 Oct 2026 · Independent Director completes second term, ceases from Sept 30 2026 | management changes | low | — | — |
| 30 Sept 2026 · 28th AGM voting results: 3 resolutions passed, 0.5% dividend declared | board shareholder meetings | low | — | — |
| 30 Sept 2026 · 28th AGM of KMS Medisurgi concluded; 3 items tabled | board shareholder meetings | low | — | — |
| 29 Sept 2026 · Trading window closure ahead of H2 FY26 results | compliance | minimal | — | — |
| 8 Sept 2026 · KMS Medisurgi files FY26 Annual Report; revenue and profit decline | results | high | — | — |
| 5 Sept 2026 · Record date fixed for Rs 0.05 per share dividend | corporate actions | medium | — | — |
| 5 Sept 2026 · KMS Medisurgi board recommends Rs 0.05 final dividend for FY26 | corporate actions | high | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.